Onesource Specialty Pharma Limited — Results, 08-07-2025: Reply to Clarification- Financial results

OneSource Specialty Pharma Limited has announced a board meeting to approve the financial results for the quarter and half-year ended March 31, 2025.

**Standalone Financial Highlights:**

- Revenue from operations surged to Rs. 4,774.14 million in Q4 from Rs. 731.43 million a year ago, driven by the consolidation of acquired businesses.

- Total income was Rs. 4,813.23 million compared to Rs. 757.77 million in the corresponding quarter last year.

- Expenses moderated at Rs. 3,064.46 million versus Rs. 1,157.68 million a year earlier, reflecting growth and integration costs.

- Profit before tax stood robust at Rs. 1,748.77 million against a loss before tax of Rs. 400.12 million a year ago.

- Full-year profit after tax returned to positive Rs. 200.00 million, reversing a significant loss of Rs. 3,649.34 million in FY24.

- EPS (basic) for FY25 was Rs. 1.81, up from a negative Rs. 87.84 in FY24.

**Balance Sheet & Financial Position:**

- Total assets expanded to Rs. 73,904.62 million from Rs. 13,085.76 million, showing substantial growth mainly due to merger and acquisition.

- Goodwill recognized at Rs. 19,761.42 million reflects premium paid for acquired businesses.

- Equity base strengthened to Rs. 59,201.01 million from Rs. 3,977.43 million after fresh equity infusion.

- Debt including lease liabilities totaled Rs. 15,242 million with a Debt-Equity ratio of 0.16x, indicating manageable leverage.

- Current liabilities slightly exceed current assets by Rs. 456.02 million.

**Cash Flows:**

- Operating cash flows were negative at Rs. 472.83 million, impacted by working capital changes post-acquisition.

- Investing cash flows used Rs. 3,000 million primarily on capex and investment in subsidiaries.

- Financing activities brought net inflows of Rs. 4,172 million due to fresh equity and debt proceeds.

**Consolidated Financials:**

- Consolidated revenue from operations was Rs. 14,448.53 million for FY25 versus Rs. 1,719.19 million last year.

- Consolidated net loss narrowed significantly to Rs. 172.81 million from a loss of Rs. 3,656.97 million in FY24.

- EPS (basic) stood at a loss of Rs. 1.57 for continuing operations and Rs. 1.63 for total operations.

- Goodwill on consolidation noted at Rs. 38,275.31 million.

**Business Updates:**

- The company has completed the merger of the CDMO and Soft Gelatin businesses of Strides Pharma and Steriscience.

- It has fully redeemed its listed non-convertible debentures.

- Management is focused on growing the CDMO segment, with several Manufacturing Services Agreements signed.

- The company has approved consolidation of its Singapore subsidiaries to improve operational efficiency.

Overall, OneSource Specialty Pharma has shown a strong rebound post-merger, with major scale-up in revenues and return to profitability on standalone basis. The integration premiums are reflected in goodwill, and the focus remains on CDMO growth and operational consolidation. Investors may note improving margins and strengthening equity base despite elevated leverage from acquisitions.